Mesoblast Limited (MEOBF)
USD 1.37
(-52.76%)
USD 1.37
(-52.76%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 667.9 Million USD | -0.04% |
| 2023 | 669.41 Million USD | 1.1% |
| 2022 | 662.14 Million USD | -11.09% |
| 2021 | 744.71 Million USD | 1.52% |
| 2020 | 733.6 Million USD | 12.5% |
| 2019 | 652.11 Million USD | -5.82% |
| 2018 | 692.44 Million USD | 5.61% |
| 2017 | 655.68 Million USD | -4.14% |
| 2016 | 684.01 Million USD | -32.8% |
| 2015 | 1.01 Billion USD | 13.19% |
| 2014 | 899.31 Million USD | 1.77% |
| 2013 | 883.71 Million USD | 22.66% |
| 2012 | 720.45 Million USD | -5.61% |
| 2011 | 763.25 Million USD | 1831.56% |
| 2010 | 39.51 Million USD | 46.49% |
| 2009 | 26.97 Million USD | -2.93% |
| 2008 | 27.78 Million USD | 30.84% |
| 2007 | 21.23 Million USD | 29.62% |
| 2006 | 16.38 Million USD | -23.67% |
| 2005 | 21.46 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 669.15 Million USD | -0.17% |
| 2024 Q2 | 670.28 Million USD | 0.0% |
| 2024 Q1 | 670.28 Million USD | 0.08% |
| 2024 Q4 | 669.15 Million USD | 0.0% |
| 2024 FY | 667.9 Million USD | -0.23% |
| 2023 Q2 | 668.06 Million USD | -2.4% |
| 2023 Q1 | 684.49 Million USD | 3.38% |
| 2023 FY | 669.41 Million USD | 1.1% |
| 2023 Q4 | 669.76 Million USD | 2.97% |
| 2023 Q3 | 650.44 Million USD | -2.64% |
| 2022 FY | 662.14 Million USD | -11.09% |
| 2022 Q3 | 681.68 Million USD | -3.23% |
| 2022 Q4 | 662.14 Million USD | -2.87% |
| 2022 Q1 | 721.81 Million USD | -3.07% |
| 2022 Q2 | 704.43 Million USD | -2.41% |
| 2021 Q2 | 687.31 Million USD | -3.55% |
| 2021 Q1 | 712.57 Million USD | -2.87% |
| 2021 FY | 744.71 Million USD | 1.52% |
| 2021 Q4 | 744.71 Million USD | -2.79% |
| 2021 Q3 | 766.12 Million USD | 11.47% |
| 2020 Q3 | 665.79 Million USD | -3.54% |
| 2020 Q4 | 733.6 Million USD | 10.19% |
| 2020 FY | 733.6 Million USD | 12.5% |
| 2020 Q1 | 653.78 Million USD | 0.26% |
| 2020 Q2 | 690.23 Million USD | 5.58% |
| 2019 Q1 | 688.78 Million USD | -0.53% |
| 2019 Q4 | 652.11 Million USD | -3.49% |
| 2019 Q2 | 688.33 Million USD | -0.07% |
| 2019 Q3 | 675.7 Million USD | -1.83% |
| 2019 FY | 652.11 Million USD | -5.82% |
| 2018 FY | 692.44 Million USD | 5.61% |
| 2018 Q4 | 692.44 Million USD | 2.15% |
| 2018 Q3 | 677.85 Million USD | 1.96% |
| 2018 Q2 | 664.81 Million USD | -1.05% |
| 2018 Q1 | 671.89 Million USD | 2.47% |
| 2017 Q3 | 679.16 Million USD | 2.77% |
| 2017 Q1 | 665.44 Million USD | -2.72% |
| 2017 Q4 | 655.68 Million USD | -3.46% |
| 2017 Q2 | 660.88 Million USD | -0.69% |
| 2017 FY | 655.68 Million USD | -4.14% |
| 2016 Q4 | 684.01 Million USD | -11.18% |
| 2016 FY | 684.01 Million USD | -32.8% |
| 2016 Q3 | 770.14 Million USD | -2.63% |
| 2016 Q2 | 790.95 Million USD | 5.06% |
| 2016 Q1 | 752.86 Million USD | -26.04% |
| 2015 Q4 | 1.01 Billion USD | 0.0% |
| 2015 Q2 | 964.58 Million USD | 18.08% |
| 2015 Q1 | 816.85 Million USD | -9.17% |
| 2015 Q3 | - USD | -100.0% |
| 2015 FY | 1.01 Billion USD | 13.19% |
| 2014 Q1 | - USD | -100.0% |
| 2014 Q4 | 899.31 Million USD | 7.86% |
| 2014 Q3 | 833.81 Million USD | -16.71% |
| 2014 Q2 | 1 Billion USD | 0.0% |
| 2014 FY | 899.31 Million USD | 1.77% |
| 2013 Q4 | 883.71 Million USD | -3.92% |
| 2013 FY | 883.71 Million USD | 22.66% |
| 2013 Q2 | 680.41 Million USD | 0.0% |
| 2013 Q3 | 919.81 Million USD | 35.18% |
| 2012 FY | 720.45 Million USD | -5.61% |
| 2012 Q4 | 720.45 Million USD | 0.0% |
| 2011 FY | 763.25 Million USD | 1831.56% |
| 2010 FY | 39.51 Million USD | 46.49% |
| 2009 FY | 26.97 Million USD | -2.93% |
| 2008 FY | 27.78 Million USD | 30.84% |
| 2007 FY | 21.23 Million USD | 29.62% |
| 2006 FY | 16.38 Million USD | -23.67% |
| 2005 FY | 21.46 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -28913344.199% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -34008.074% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -6228.412% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -120870.181% |
| Rebus Holdings, Inc. | 5000.00 USD | -13357911.22% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -412.938% |
| Qrons Inc. | 420.00 USD | -159023843.095% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -86567.847% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -2290.139% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -138884.67% |
| Skye Bioscience, Inc. | 11.94 Million USD | -5493.614% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -1619.311% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -9151.005% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -874642.071% |
| SQZ Biotechnologies Company | 107.18 Million USD | -523.117% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -46540.058% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -922860.77% |
| Marizyme, Inc. | 22.01 Million USD | -2933.833% |
| Genus plc | 1.02 Billion USD | 35.086% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -49069.882% |
| Pharming Group N.V. | 462.85 Million USD | -44.3% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -20059.92% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -133737.348% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -106423.215% |
| ContraFect Corporation | 20.67 Million USD | -3129.849% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -170995.987% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -174662.103% |
| IMV Inc. | 31.33 Million USD | -2031.567% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -16009.431% |
| MultiCell Technologies, Inc. | 126.22 USD | -529155787.34% |
| ONE Bio Corp. | 70.08 Million USD | -852.98% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -70976.767% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -419.727% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -154609.034% |
| Q BioMed Inc. | 3.51 Million USD | -18898.644% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -1798.577% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -255529.298% |
| Biomind Labs Inc. | 73.81 Thousand USD | -904681.372% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -49.65% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -45998.891% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -2125.226% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -24219.705% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -97051.151% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -25556.945% |
| GB Sciences, Inc. | 103.44 Thousand USD | -645576.38% |
| Alpha Cognition Inc. | 2.45 Million USD | -27137.123% |
| HST Global, Inc. | 1526.00 USD | -43767957.733% |
| CSL Limited | 38.02 Billion USD | 98.243% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -67503.529% |
| Halberd Corporation | 10.13 Thousand USD | -6592542.0% |
| Enzolytics Inc. | 361.7 Million USD | -84.653% |
| Agentix Corp. | 261.39 Thousand USD | -255416.833% |
| Resverlogix Corp. | 8.11 Million USD | -8130.444% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -35466.733% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 85.296% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -1300.152% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -104315.586% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -2931731.618% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -7363.281% |
| AVAX Technologies, Inc. | 7.37 Million USD | -8953.631% |
| Zenith Capital Corp. | 7410.00 USD | -9013402.848% |
| Genscript Biotech Corporation | 3.38 Billion USD | 80.277% |
| Ember Therapeutics, Inc. | 184.00 USD | -362989335.326% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -207447.579% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -255444.207% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -71875.068% |
| Kadimastem Ltd | 2.3 Million USD | -28887.733% |
| Helix BioMedix, Inc. | 3.02 Million USD | -21978.73% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -1167.339% |
| BioStem Technologies, Inc. | 14.56 Million USD | -4487.137% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1169726.183% |
| LadRx Corporation | 2.3 Million USD | -28839.979% |
| Cell Source, Inc. | 195.17 Thousand USD | -342113.014% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -188776.825% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -188776.825% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1072867.101% |
| Affymax, Inc. | 7.44 Million USD | -8873.54% |
| Itoco Inc. | 1.4 Million USD | -47604.73% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -698124.449% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -629994.869% |
| Mobile Lads Corp. | 52.00 USD | -1284424055.769% |
| CytoDyn Inc. | 11.13 Million USD | -5897.67% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -467054.8% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -3735361.751% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -173168.692% |
| SYBLEU INC | 330.46 Thousand USD | -202007.484% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -163032.553% |
| International Stem Cell Corporation | 5.39 Million USD | -12291.476% |
| Bioxytran, Inc. | 137.63 Thousand USD | -485158.839% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -4352.127% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -3928.594% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -845343.748% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -77142.781% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -8785.201% |
| Neutra Corp. | 2851.00 USD | -23426787.443% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1961.04% |
| PureTech Health plc | 693.97 Million USD | 3.757% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -8175.222% |
| IXICO plc | 15.84 Million USD | -4115.505% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -7964.484% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -546.414% |
| CSL Limited | 38.02 Billion USD | 98.243% |
| Cellectis S.A. | 333.99 Million USD | -99.973% |